THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen Inc. (NASDAQ: AMGN) today announced data from two Phase 3 studies which evaluated the administration of Nplate™ (romiplostim) on increasing and sustaining platelet counts in both splenectomized (spleen removed) and non-splenectomized patients with chronic Immune Thrombocytopenic Purpura (ITP). The data will be published in the Feb. 2, 2008, issue of The Lancet.
